{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:07:01Z","timestamp":1788570421942,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"dept of health research, govt of india","award":["HTA-Resource centre grant"],"award-info":[{"award-number":["HTA-Resource centre grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00228-021-03242-6","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T19:02:17Z","timestamp":1635361337000},"page":"351-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-767X","authenticated-orcid":false,"given":"Bhavani Shankara","family":"Bagepally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Sasidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"9 Suppl","key":"3242_CR1","first-page":"S139","volume":"23","author":"S Karr","year":"2017","unstructured":"Karr S (2017) Epidemiology and management of hyperlipidemia. Am J Manag Care 23(9 Suppl):S139\u2013S148","journal-title":"Am J Manag Care"},{"issue":"15","key":"3242_CR2","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese EP, Robinson JG, Kowalewski M et al (2018) Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319(15):1566\u20131579. https:\/\/doi.org\/10.1001\/jama.2018.2525","journal-title":"JAMA"},{"issue":"5","key":"3242_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.7326\/M14-0126","volume":"160","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et al (2014) Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology\/American Heart Association cholesterol guideline. Ann Intern Med 160(5):339\u2013343. https:\/\/doi.org\/10.7326\/M14-0126","journal-title":"Ann Intern Med"},{"key":"3242_CR4","doi-asserted-by":"publisher","unstructured":"Efficacy and safety (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet 385(9976):1397\u20131405. https:\/\/doi.org\/10.1016\/S0140-6736(14)61368-4","DOI":"10.1016\/S0140-6736(14)61368-4"},{"issue":"9841","key":"3242_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England) 380(9841):581\u2013590","journal-title":"Lancet (London, England)"},{"issue":"2","key":"3242_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00129784-200707020-00005","volume":"7","author":"AA Bavry","year":"2007","unstructured":"Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL (2007) Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs 7(2):135\u2013141. https:\/\/doi.org\/10.2165\/00129784-200707020-00005","journal-title":"Am J Cardiovasc Drugs"},{"key":"3242_CR7","doi-asserted-by":"publisher","unstructured":"Brugts JJ, Yetgin T, Hoeks SE et al (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338(jun30 1):b2376-b2376. https:\/\/doi.org\/10.1136\/bmj.b2376","DOI":"10.1136\/bmj.b2376"},{"key":"3242_CR8","doi-asserted-by":"crossref","unstructured":"Tataronis GR (2006) Statin-related adverse events: a meta-analysis. Clinical Therapeutics 28(1)","DOI":"10.1016\/j.clinthera.2006.01.005"},{"issue":"5","key":"3242_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S et al (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64(5):485\u2013494","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3242_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","volume":"9","author":"R Chaudhary","year":"2017","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A (2017) PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol 9(2):76\u201391. https:\/\/doi.org\/10.4330\/wjc.v9.i2.76","journal-title":"World J Cardiol"},{"issue":"6","key":"3242_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.18553\/jmcp.2016.22.6.641","volume":"22","author":"M McDonagh","year":"2016","unstructured":"McDonagh M, Peterson K, Holzhammer B, Fazio S (2016) A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm 22(6):641\u2013653q. https:\/\/doi.org\/10.18553\/jmcp.2016.22.6.641","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"3242_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"issue":"10","key":"3242_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","volume":"119","author":"A Baruch","year":"2017","unstructured":"Baruch A, Mosesova S, Davis JD et al (2017) Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study). Am J Cardiol 119(10):1576\u20131583. https:\/\/doi.org\/10.1016\/j.amjcard.2017.02.020","journal-title":"Am J Cardiol"},{"issue":"2","key":"3242_CR14","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","volume":"309","author":"K Miyosawa","year":"2015","unstructured":"Miyosawa K, Watanabe Y, Murakami K et al (2015) New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J Physiol-Endocrinol Metab 309(2):E177\u2013E190. https:\/\/doi.org\/10.1152\/ajpendo.00528.2014","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"12","key":"3242_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.5414\/CP203418","volume":"57","author":"K Yokote","year":"2019","unstructured":"Yokote K, Suzuki A, Li Y, Matsuoka N, Teramoto T (2019) Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects. Int J Clin Pharmacol Ther 57(12):575\u2013589. https:\/\/doi.org\/10.5414\/CP203418","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"16","key":"3242_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P et al (2017) Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376(16):1527\u20131539. https:\/\/doi.org\/10.1056\/NEJMoa1701488","journal-title":"N Engl J Med"},{"issue":"22","key":"3242_CR17","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379(22):2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"issue":"15","key":"3242_CR18","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376(15):1430\u20131440. https:\/\/doi.org\/10.1056\/NEJMoa1615758","journal-title":"N Engl J Med"},{"issue":"9","key":"3242_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M (2019) Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 42(9):1029\u20131039. https:\/\/doi.org\/10.1007\/s40618-019-01019-4","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"3242_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s11739-017-1708-7","volume":"12","author":"A Squizzato","year":"2017","unstructured":"Squizzato A, Suter MB, Nerone M et al (2017) PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med 12(7):1043\u20131053. https:\/\/doi.org\/10.1007\/s11739-017-1708-7","journal-title":"Intern Emerg Med"},{"issue":"6","key":"3242_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO et al (2016) The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 37(6):536\u2013545. https:\/\/doi.org\/10.1093\/eurheartj\/ehv563","journal-title":"Eur Heart J"},{"key":"3242_CR22","doi-asserted-by":"publisher","unstructured":"Li C, Lin L, Zhang W et al (2015) Efficiency and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibody on hypercholesterolemia: a meta\u2010analysis of 20 randomized controlled trials. JAHA 4(6). https:\/\/doi.org\/10.1161\/JAHA.115.001937","DOI":"10.1161\/JAHA.115.001937"},{"issue":"1","key":"3242_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7326\/M14-2957","volume":"163","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Kolodziejczak M, Schulze V et al (2015) Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 163(1):40\u201351. https:\/\/doi.org\/10.7326\/M14-2957","journal-title":"Ann Intern Med"},{"key":"3242_CR24","doi-asserted-by":"publisher","unstructured":"Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP (2017) PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 4:CD011748. https:\/\/doi.org\/10.1002\/14651858.CD011748.pub2","DOI":"10.1002\/14651858.CD011748.pub2"},{"key":"3242_CR25","doi-asserted-by":"publisher","unstructured":"Schmidt AF, Carter J-PL, Pearce LS et al (2010) PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 10:CD011748. https:\/\/doi.org\/10.1002\/14651858.CD011748.pub3","DOI":"10.1002\/14651858.CD011748.pub3"},{"issue":"1","key":"3242_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"21","key":"3242_CR27","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","volume":"70","author":"MA Hlatky","year":"2017","unstructured":"Hlatky MA, Kazi DS (2017) PCSK9 inhibitors: economics and policy. J Am Coll Cardiol 70(21):2677\u20132687. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.001","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3242_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/clc.22535","volume":"39","author":"SR Gandra","year":"2016","unstructured":"Gandra SR, Villa G, Fonarow GC et al (2016) Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 39(6):313\u2013320. https:\/\/doi.org\/10.1002\/clc.22535","journal-title":"Clin Cardiol"},{"issue":"6","key":"3242_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","volume":"20","author":"PP Toth","year":"2017","unstructured":"Toth PP, Danese M, Villa G et al (2017) Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ 20(6):555\u2013564. https:\/\/doi.org\/10.1080\/13696998.2017.1284078","journal-title":"J Med Econ"},{"issue":"10","key":"3242_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow GC, Keech AC, Pedersen TR et al (2017) Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2(10):1069. https:\/\/doi.org\/10.1001\/jamacardio.2017.2762","journal-title":"JAMA Cardiol"},{"issue":"7","key":"3242_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG et al (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316(7):743. https:\/\/doi.org\/10.1001\/jama.2016.11004","journal-title":"JAMA"},{"key":"3242_CR32","doi-asserted-by":"publisher","unstructured":"Korman M, Wisl\u00f8ff T (2018) Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Euro Heart J Cardiovas Pharmacotherapy 4(1):15\u201322. https:\/\/doi.org\/10.1093\/ehjcvp\/pvx010","DOI":"10.1093\/ehjcvp\/pvx010"},{"key":"3242_CR33","doi-asserted-by":"publisher","unstructured":"PRISMA-P Group, Moher D, Shamseer L et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","DOI":"10.1186\/2046-4053-4-1"},{"key":"3242_CR34","unstructured":"CEA Registry (2021) Center for the Evaluation of Value and Risk in Health. Accessed April 18, 2021. https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry"},{"issue":"1","key":"3242_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"3242_CR36","unstructured":"Rohatgi A (2020) WebPlotDigitizer. Accessed April 19, 2021. https:\/\/automeris.io\/WebPlotDigitizer"},{"issue":"4","key":"3242_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA (2016) Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res 16(4):513\u2013523. https:\/\/doi.org\/10.1586\/14737167.2015.1103185","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3242_CR38","doi-asserted-by":"publisher","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clinic Epidemiol 64(4):383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"3242_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","volume":"87","author":"M Hultcrantz","year":"2017","unstructured":"Hultcrantz M, Rind D, Akl EA et al (2017) The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol 87:4\u201313. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.05.006","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3242_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-139","volume":"14","author":"C Crespo","year":"2014","unstructured":"Crespo C, Monleon A, D\u00edaz W, R\u00edos M (2014) Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol 14(1):1\u20139","journal-title":"BMC Med Res Methodol"},{"key":"3242_CR41","doi-asserted-by":"crossref","unstructured":"Stinnett AA, Mullahy J (1998) Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18(2_suppl):S68-S80","DOI":"10.1177\/0272989X98018002S09"},{"issue":"7","key":"3242_CR42","doi-asserted-by":"publisher","first-page":"A705","DOI":"10.1016\/j.jval.2015.09.2644","volume":"18","author":"J O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony J (2015) The limitations of Icers in screening interventions and the relative net benefit alternative. Value in Health 18(7):A705","journal-title":"Value in Health"},{"key":"3242_CR43","doi-asserted-by":"publisher","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A (2020) Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. In Review https:\/\/doi.org\/10.21203\/rs.3.rs-93779\/v1","DOI":"10.21203\/rs.3.rs-93779\/v1"},{"key":"3242_CR44","doi-asserted-by":"crossref","unstructured":"Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA, Thakkinstian A (2019) Systematic review and meta-analysis of cost-effectiveness of rotavirus vaccine in low-income and lower-middle-income countries. In: Vol 6. Oxford University Press US ofz117","DOI":"10.1093\/ofid\/ofz117"},{"issue":"12","key":"3242_CR45","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jval.2019.09.2750","volume":"22","author":"BS Bagepally","year":"2019","unstructured":"Bagepally BS, Gurav YK, Anothaisintawee T, Youngkong S, Chaikledkaew U, Thakkinstian A (2019) Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis. Value in Health 22(12):1458\u20131469. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2750","journal-title":"Value in Health"},{"issue":"1","key":"3242_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001020","volume":"8","author":"BS Bagepally","year":"2020","unstructured":"Bagepally BS, Chaikledkaew U, Gurav YK et al (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care 8(1):e001020. https:\/\/doi.org\/10.1136\/bmjdrc-2019-001020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3242_CR47","unstructured":"Edejer TT-T WHO guide to cost-effectiveness analysis: making choices in health. World Health Organization"},{"key":"3242_CR48","unstructured":"World Bank Country and Lending Groups \u2013 World Bank Data Help Desk (2021) Accessed April 18, 2021. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"3242_CR49","unstructured":"StataCorp L (2017) Stata statistical software. Release 16.[software]. College Station, TX. Published online"},{"issue":"10","key":"3242_CR50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jval.2017.05.014","volume":"20","author":"W-H Cheng","year":"2017","unstructured":"Cheng W-H, Gaudette \u00c9, Goldman DP (2017) PCSK9 inhibitors show value for patients and the US health care system. Value in Health 20(10):1270\u20131278. https:\/\/doi.org\/10.1016\/j.jval.2017.05.014","journal-title":"Value in Health"},{"key":"3242_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2019.106566","volume":"120","author":"A Dressel","year":"2019","unstructured":"Dressel A, Schmidt B, Schmidt N et al (2019) Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: insights from the Ludwigshafen risk and cardiovascular health cohort. Vascul Pharmacol 120:106566. https:\/\/doi.org\/10.1016\/j.vph.2019.106566","journal-title":"Vascul Pharmacol"},{"issue":"7","key":"3242_CR52","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamacardio.2019.1647","volume":"4","author":"GC Fonarow","year":"2019","unstructured":"Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiol 4(7):691. https:\/\/doi.org\/10.1001\/jamacardio.2019.1647","journal-title":"JAMA Cardiol"},{"key":"3242_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijcard.2017.10.080","volume":"253","author":"MC Stam-Slob","year":"2018","unstructured":"Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ (2018) Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 253:148\u2013154. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.080","journal-title":"Int J Cardiol"},{"issue":"4","key":"3242_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.clinthera.2017.02.011","volume":"39","author":"G Villa","year":"2017","unstructured":"Villa G, Lothgren M, Kutikova L et al (2017) Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther 39(4):771-786.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.011","journal-title":"Clin Ther"},{"key":"3242_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.06.900","volume":"287","author":"T Wisl\u00f8ff","year":"2019","unstructured":"Wisl\u00f8ff T, Mundal LJ, Retterst\u00f8l K, Igland J, Kristiansen IS (2019) Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: methodological aspects. Atherosclerosis 287:140\u2013146. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.06.900","journal-title":"Atherosclerosis"},{"issue":"10","key":"3242_CR56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40273-019-00820-6","volume":"37","author":"K Kongpakwattana","year":"2019","unstructured":"Kongpakwattana K, Ademi Z, Chaiyasothi T et al (2019) Cost-effectiveness analysis of non-statin lipid-modifying agents for secondary cardiovascular disease prevention among statin-treated patients in Thailand. Pharmacoeconomics 37(10):1277\u20131286. https:\/\/doi.org\/10.1007\/s40273-019-00820-6","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"3242_CR57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40273-020-00948-w","volume":"38","author":"N Kam","year":"2020","unstructured":"Kam N, Perera K, Zomer E, Liew D, Ademi Z (2020) Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: a cost-effectiveness analysis. Pharmacoeconomics 38(9):1007\u20131020. https:\/\/doi.org\/10.1007\/s40273-020-00948-w","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3242_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M18-1776","volume":"170","author":"DS Kazi","year":"2019","unstructured":"Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K (2019) Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med 170(4):221. https:\/\/doi.org\/10.7326\/M18-1776","journal-title":"Ann Intern Med"},{"issue":"8","key":"3242_CR59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","volume":"318","author":"DS Kazi","year":"2017","unstructured":"Kazi DS, Penko J, Coxson PG et al (2017) Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318(8):748. https:\/\/doi.org\/10.1001\/jama.2017.9924","journal-title":"JAMA"},{"issue":"12","key":"3242_CR60","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","volume":"2","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol 2(12):1369. https:\/\/doi.org\/10.1001\/jamacardio.2017.3655","journal-title":"JAMA Cardiol"},{"key":"3242_CR61","doi-asserted-by":"publisher","unstructured":"Liang Z, Chen Q, Wei R et al (2021) Cost-effectiveness of alirocumab for the secondary prevention of cardiovascular events after myocardial infarction in the Chinese setting. Front Pharmacol 12((Liang Z.; Zhang X.; Chen X.; Zhao Q., zhaoquanming1@sina.com) Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China). https:\/\/doi.org\/10.3389\/fphar.2021.648244","DOI":"10.3389\/fphar.2021.648244"},{"key":"3242_CR62","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.04.122","volume":"267","author":"R Kumar","year":"2018","unstructured":"Kumar R, Tonkin A, Liew D, Zomer E (2018) The cost-effectiveness of PCSK9 inhibitors - the Australian healthcare perspective. Int J Cardiol 267:183\u2013187. https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.122","journal-title":"Int J Cardiol"},{"issue":"1","key":"3242_CR63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41512-020-00072-5","volume":"4","author":"GFN Berkelmans","year":"2020","unstructured":"Berkelmans GFN, Greving JP, van der Graaf Y, Visseren FLJ, Dorresteijn JAN (2020) Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective? Diagn Progn Res 4(1):4. https:\/\/doi.org\/10.1186\/s41512-020-00072-5","journal-title":"Diagn Progn Res"},{"key":"3242_CR64","doi-asserted-by":"publisher","unstructured":"Xi X, Wang X, Xie W et al (2021) Cost-effectiveness analysis of evolocumab in patients with recent acute coronary syndrome in China. In Review https:\/\/doi.org\/10.21203\/rs.3.rs-464160\/v1","DOI":"10.21203\/rs.3.rs-464160\/v1"},{"key":"3242_CR65","doi-asserted-by":"publisher","unstructured":"Liang Z, Chen Q, Yang F et al (2020) Cost-effectiveness of evolocumab therapy for myocardial infarction: the Chinese healthcare perspective. Cardiovasc Drugs Ther. 2020 ((Liang Z.; Yan X.; Zhang X.; Chen X.; Zhao Q., zhaoquanming1@sina.com) Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China). https:\/\/doi.org\/10.1007\/s10557-020-07079-6","DOI":"10.1007\/s10557-020-07079-6"},{"issue":"10","key":"3242_CR66","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1253\/circj.CJ-17-1455","volume":"82","author":"S Kodera","year":"2018","unstructured":"Kodera S, Morita H, Kiyosue A, Ando J, Takura T, Komuro I (2018) Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coronary artery disease in Japan. Circ J 82(10):2602\u20132608. https:\/\/doi.org\/10.1253\/circj.CJ-17-1455","journal-title":"Circ J"},{"issue":"18","key":"3242_CR67","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","volume":"75","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Briggs AH, Reed SD et al (2020) Cost-effectiveness of alirocumab in patients with acute coronary syndromes. J Am Coll Cardiol 75(18):2297\u20132308. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.029","journal-title":"J Am Coll Cardiol"},{"key":"3242_CR68","doi-asserted-by":"publisher","unstructured":"Landmesser U, Lindgren P, Hagstr\u00f6m E et al (2020) Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual Care Clin Outcomes. 2020 ((Landmesser U.) Medical Director Charit\u00e9 Cardiovascular Center (CC11), Campus Benjamin Franklin Charit\u00e9-Universit\u00e4tsmedizin Berlin, Hindenburgdamm 30, Germany). https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa072","DOI":"10.1093\/ehjqcco\/qcaa072"},{"key":"3242_CR69","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jclinepi.2020.09.018","volume":"129","author":"JL Brozek","year":"2021","unstructured":"Brozek JL, Canelo-Aybar C, Akl EA et al (2021) GRADE guidelines 30: the GRADE approach to assessing the certainty of modeled evidence\u2014an overview in the context of health decision-making. J Clin Epidemiol 129:138\u2013150. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.09.018","journal-title":"J Clin Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03242-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T04:15:34Z","timestamp":1644207334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03242-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}